How a toxic protein affects energy-producing structures in Alzheimer's disease

Mitochondrial liquid-liquid phase separation in Alzheimer's disease

NIH-funded research University of Minnesota · NIH-11057179

This study is looking at how a harmful protein related to Alzheimer's disease affects the tiny powerhouses in our cells that produce energy, and it's designed for anyone interested in understanding more about how this protein might disrupt cell health in Alzheimer's.

Quick facts

Grant typeR03 grant
Study typeNIH-funded research
Funding institutionUniversity of Minnesota NIH-funded
Lab location1 site (Minneapolis, United States)
Project IDNIH-11057179 on NIH RePORTER

What this research studies

This research investigates the effects of a toxic protein called Aβ42 on mitochondria, the energy-producing structures in cells, specifically in the context of Alzheimer's disease. The study aims to understand how Aβ42 disrupts mitochondrial functions and gene expression, which are crucial for maintaining mitochondrial health. By using a basic cell model, researchers will explore the mechanisms behind these disruptions and how they contribute to the disease. The project also includes innovative techniques to control Aβ42 and observe its impact on mitochondrial dynamics.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk due to advanced age.

Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatment strategies that target mitochondrial dysfunction in Alzheimer's disease.

How similar studies have performed: While the specific approach of investigating Aβ42's impact on mitochondrial phase separation is novel, related research has shown promising results in understanding mitochondrial dysfunction in Alzheimer's disease.

Where this research is happening

Minneapolis, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.